Literature DB >> 25204488

A comparative study on immunomodulatory activity of polysaccharides from two official species of Ganoderma (Lingzhi).

Lan-Zhen Meng1, Jing Xie, Guang-Ping Lv, De-Jun Hu, Jing Zhao, Jin-Ao Duan, Shao-Ping Li.   

Abstract

Two Ganoderma species, G. lucidum and G. sinense, are listed as Lingzhi in Chinese Pharmacopoeia and they are considered to have the same therapeutic effects. Polysaccharides were the main immunomodulatory and anticancer components in Ganoderma. In this study, the chemical characters and the effects of polysaccharides from G. lucidum (GLPS) and G. sinense (GSPS) on macrophage functions were investigated and compared. Chemical studies showed that GLPS and GSPS were different, displaying various molecular weight distribution and ratio of monosaccharide components. In vitro pharmacological studies showed that both GLPS and GSPS had potent effects on macrophage functions, such as promoting macrophage phagocytosis, increasing their release of nitric oxide and cytokines interleukin (IL)-1α, IL-6, IL-10, and tumor necrosis factor-α. Generally, GLPS was more powerful than GSPS. This study is helpful to elucidate the active components and pharmacological variation between the 2 Ganoderma species. The structure-activity relationship of polysaccharides from Ganoderma needs further study.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25204488     DOI: 10.1080/01635581.2014.948215

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  6 in total

1.  Evaluation on quality consistency of Ganoderma lucidum dietary supplements collected in the United States.

Authors:  Ding-Tao Wu; Yong Deng; Ling-Xiao Chen; Jing Zhao; Anton Bzhelyansky; Shao-Ping Li
Journal:  Sci Rep       Date:  2017-08-10       Impact factor: 4.379

2.  Therapeutic Effect of Astragalus Polysaccharides on Hepatocellular Carcinoma H22-Bearing Mice.

Authors:  Xiaoyu Lai; Weibiao Xia; Jing Wei; Xinghong Ding
Journal:  Dose Response       Date:  2017-01-03       Impact factor: 2.658

3.  Recombinant Expression and Bioactivity Comparison of Four Typical Fungal Immunomodulatory Proteins from Three Main Ganoderma Species.

Authors:  Zheng-Wei Qu; Si-Ya Zhou; Shi-Xin Guan; Rui Gao; Zuo-Wen Duan; Xin Zhang; Wei-Yan Sun; Wen-Li Fan; Shui-Sen Chen; Li-Jing Chen; Jing-Wei Lin; Yan-Ye Ruan
Journal:  BMC Biotechnol       Date:  2018-12-14       Impact factor: 2.563

Review 4.  Ganoderma: A Cancer Immunotherapy Review.

Authors:  Yu Cao; Xiaowei Xu; Shujing Liu; Linfang Huang; Jian Gu
Journal:  Front Pharmacol       Date:  2018-10-25       Impact factor: 5.810

Review 5.  Chemical, biochemical, preclinical and clinical studies of Ganoderma lucidum polysaccharide as an approved drug for treating myopathy and other diseases in China.

Authors:  Pengjiao Zeng; Zhihua Guo; Xuan Zeng; Cui Hao; Yiran Zhang; Meng Zhang; Yong Liu; Hui Li; Juan Li; Lijuan Zhang
Journal:  J Cell Mol Med       Date:  2018-04-24       Impact factor: 5.310

6.  Associated Targets of the Antioxidant Cardioprotection of Ganoderma lucidum in Diabetic Cardiomyopathy by Using Open Targets Platform: A Systematic Review.

Authors:  Fahmi Shaher; Hongbin Qiu; Shuqiu Wang; Yu Hu; Weiqun Wang; Yu Zhang; Yao Wei; Hisham Al-Ward; Mahfoudh A M Abdulghani; Sattam Khulaif Alenezi; Salem Baldi; Shaobo Zhou
Journal:  Biomed Res Int       Date:  2020-07-25       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.